Clinical trial
Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors
NCT00084786 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00084786 |
|---|---|
| Title | Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors |
| Official title | A Phase I Dose Escalation of ZD1839 (Iressa®) (Days 1 and 2) and Docetaxel (Day 3) Every 3 Weeks in Patients With an Advanced Solid Tumor |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | docetaxel, gefitinib |
| Start date | Mar 1, 2004 |
| Primary completion | Jul 1, 2006 |
| First posted | Jun 11, 2004 |
| Last update posted | Jan 17, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: